Exploring treatment characteristics of patients with hereditary transthyretin amyloidosis 

Chafic Karam, MD, University of Pennsylvania, Philadelphia, PA, discusses a recent publication on the treatment characteristics of patients with hereditary transthyretin (ATTR) amyloidosis. The study examines FDA approved agents such as tafamidis, patisiran, inotersen, and vutrisiran, for cardiac and neuropathic amyloidosis. The complexities of treating patients with mixed phenotypes and the safety and efficacy of combination therapies are highlighted. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.